Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative of the effect about CAVI between Luseogliflozin and Amaryl in type2 diabetes

Trial Profile

Comparative of the effect about CAVI between Luseogliflozin and Amaryl in type2 diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glimepiride (Primary) ; Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2019 According to UMIN, the date for data entry closure is 31 Jan 2019, and the date for conclusion of data analysis is 31 March 2019.
    • 05 Apr 2019 Status changed from not yet recruiting to completed.
    • 27 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top